ECCN European Conference on Clinical Neuroimaging - PARIS France 2020



Dr. Javier Arbizu, MD, PhD, is Professor of Radiology and Nuclear Medicine at the University of Navarra, and Director of Neuroimaging and Radionuclide Therapy Section at the University of Navarra Clinic, (Pamplona, Spain). During his career he has had the opportunity to work in the Nuclear Cardiology Laboratory at the Mount Sinai Medical Center, (New York, USA), PET Center of the Department of Radiology at the University of Pittsburgh Medical Center (Pittsburgh, USA), and MRC-Hammersmith (London, UK).
As Nuclear Medicine physician, he has dedicated most of his time to work on neuroimaging both in clinical assistance and research, particularly interested in clinical and prodromal neurodegenerative disorders, and neurooncology. He is currently leading the Spanish amyloid PET imaging registry project founde by the Government of Spain and Industry.
Dr. Arbizu is member of the Executive Board of the Spanish Society of Nuclear Medicine (SEMNIM), and involved in the Neuroimaging Committee of the EANMMI and in the Brain Imaging Council of the SNMMI as Board of director’s treasurer. He is member of the Editorial Board of the Eur J Nucl Med Mol Imaging, and Rev Esp Med Nucl Med Imagen Mol.




Henryk Barthel, MD, PhD, is Full Professor and Assistant Medical Director of the Department of Nuclear Medicine of the University Hospital Leipzig (Germany). He underwent training in Nuclear Medicine in Heidelberg and Leipzig. From 2000 to 2003 he worked as a Research Fellow at the Imperial College Hammersmith Hospital in London (UK). 
Prof. Barthel’s current preclinical and clinical research activities focus on new PET imaging techniques to improve diagnosis and treatment in Alzheimer’s disease and stroke, as well as on combined brain PET-MR imaging. To support the general progress of brain imaging, he serves as Immediate Past-President of the SNMMI Brain Imaging Council and as member of the Working Group Neuro-Nuclear Medicine of the German Society of Nuclear Medicine.



Alexander DRZEZGA

Alexander Drzezga is Head of the Department of Nuclear Medicine at the University Hospital of Cologne and full Professor at the University of Cologne. He received his MD degree from Technische Universität München (TUM), Munich, Germany and is a board certified nuclear medicine physician since 2003. Since 2005 he has been Assistant Professor for Nuclear Medicine of the Department of Nuclear Medicine at TUM. In 2009, he joined the Martinos Center for Biological Imaging, Harvard University, Boston, USA as a Visiting Professor. In 2011 he was awarded a “Heisenberg-Professorship” for Multimodal Imaging at TUM, Munich, Germany. In October 2012, he accepted a position as Professor and Chair of Nuclear Medicine at the University of Cologne. His research focuses on multimodal neuroimaging (PET/CT, MRI, fMRI, PET/MR) in aging and neurodegeneration, on development and evaluation of novel tracers/radiopharmaceuticals and on molecular/multimodal imaging for therapy monitoring in oncology and personalized medicine.



Professor Dr. Swen Hesse, MD is a nuclear medicine physician and a Full Professor for Molecular Imaging at the Integrated Research and Treatment Center (IFB) AdiposityDiseases and the Department of Nuclear Medicine, University Medical Center, University of Leipzig, Germany. He serves as the Chair of the Neuroimaging Committee of the European Association of Nuclear Medicine and Molecular Imaging (EANM). Swen Hesse has extensive experience in Neurotransmitter PET imaging in clinical research as Principal Investigator or Co-Investigator of numerous third-party funded research projects on brain PET/SPECT imaging in neuropsychiatric disorders including European Multicenter Studies. His current work focuses on integrative, PETMR studies on neurobiological underpinnings of behavior.


Prof Dr  K.L. Leenders is a clinical neurologist who trained at the University of Amsterdam and who became board licensed in 1980 in The Netherlands.
Since 1998 he has taken the position of professor of neurology at the Department of Neurology at the University Medical Centre Groningen (UMCG), The Netherlands. One of the main themes of his research program involves PET radiotracer studies of metabolic and neurotransmitter changes in Parkinson's disease, Huntington’s disease and dystonia. During the last few years fMRI and FDG PET studies have increasingly become an important part of his program. In particular the covariance analysis and related procedures in brain degenerative diseases have become a main focus of interest. Collaborations exist with many groups on a national and international basis.



Silvia Morbelli (MD, PhD) is a Full Staff Physician at the IRCCS San Martino-IST University Hospital and a Contract Professor of the School of Specialization in Nuclear Medicine at the University of Genoa. She specialized in Nuclear Medicine in 2005 and obtained a PhD in Applied Neurosciences in 2010.  She has made contributions to aspects related to the diagnostic and physiopathological role of functional imaging in neurodegenerative diseases. She is especially interested in the use of neuroimaging tools as disease biomarkers in the earliest and preclinical stages of Alzheimer’s disease and Movement Disorders. Dr Morbelli has a track record of 90 publications, an H index of 19 and over 1100 citations (ISI, Web of Science) and she has been invited to hold more than 50 presentations to national and international meetings. She acted as instructor of PET and SPECT imaging in Movement Disorders at the European School of Nuclear Medicine in 2015 and 2016. She is since 2015 member of the Neuroimaging Committee of the European Association of Nuclear Medicine.



Flavio Nobili is Associate Professor of Neurology at the University of Genoa (I), Dept of Neuroscience (DINOGMI). He works as a neurologist at the University Hospital ‘San Martino’ in Genoa (I) where he leads the Unit for Cognitive Disorders. He has conducted pharma clinical trials (phase II and III) in AD for more than 10 years as Principal Investigator. His own expertise includes structural and functional neuroimaging, neuropsychology, qEEG, Doppler sonography of brain vessels, and clinical assessment. 
He and his Unit are part of the European Alzheimer Disease Consortium (EADC) since 2002 to date. At the EADC he leads the PET study group since 2008 to date, focusing on FDG-PET and MCI and now on amyloid PET and cognitive disorders more in general. This has produced some top publications. 
He has been a member of the Neuroimaging Committee of the European Association of Nuclear Medicine (EANM) between 2008 and 2014. He co-authored the four procedural EANM guidelines for the acquisition of perfusion SPECT, FDG-PET, DAT SPECT and SPECT with D2 receptor tracers in 2009-2010. He has coauthored the Italian recommendations for the clinical use of amyloid PET in 2015. He is presently leading a panel of experts preparing the recommendations of the European Academy of Neurology and of the EANM on the use of FDG-PET in dementia. 




Agneta Nordberg is Professor in Clinical Neuroscience, Karolinska Institutet, Director Center for Alzheimer Research, Translational Alzheimer Neurobiology ,Senior.
Consultant in Geriatric Medicine, Karolinska University Hospital Huddinge, She is External PhD thesis examiner for 12 PhD thesis and External reviewer of 13 academically appointments.She is also the Organizer of 16 international symposia and conferences. And Principle Investigator for more than 15 clinical trials.
She received many awards among which the 2014 Queen Silvia prize for outstanding Alzheimer research, the  2013 Wailet and Eric Forsgren prize for prominent Alzheimer research, 2006 Alois Alzheimer Award.


Marco Pagani [Medical Doctor, 1985; PhD in Brain Neurophysiology and Nuclear Medicine Methodology, 2000, at Karolinska Institute of Stockholm] is Senior Researcher at the Institute of Cognitive Sciences and Technologies of the Italian National Research Council (ISTC-CNR) and is Senior Member of the European Neuroimaging Committee of EANM. His work focuses on the physiopathology of cerebral blood flow, metabolism and brain anatomy, applied to neurodegenerative, neurological and psychiatric disorders. One of the most relevant research lines he has pursued is the implementation of multivariate analysis and the relative identification of brain networking in normal and pathological conditions. 



Dr. Rabinovici is an Associate Professor of Neurology at the University of California Memory & Aging Center (UCSF-MAC). He received his Bachelor’s of Science from Stanford University and M.D. from Northwestern University Medical School. He completed an internship in internal medicine at Stanford University, neurology residency (and chief residency) at UCSF and a behavioral neurology fellowship at the MAC. Dr. Rabinovici leads the MAC PET imaging program and is principle investigator of Imaging Dementia: Evidence for Amyloid Scanning (IDEAS), a U.S.-wide study to assess the clinical utility of amyloid PET in ~18,500 patients meeting Appropriate Use Criteria for amyloid imaging. His work investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and to study the pathophysiology of neurodegenerative diseases. Dr. Rabinovici’s lab is supported by the National Institutes of Health, the Alzheimer’s Association, the American College of Radiology, the Tau Consortium, the John Douglas French Alzheimer's Foundation, the Association for Frontotemporal Lobar Degeneration, the Michael J. Fox Foundation as well as industry partners. Awards recognizing his work include the 2015 Christopher Clark Award for Advancement of the Field of Amyloid Imaging, the 2012 American Academy of Neurology Research Award in Geriatric Neurology and the 2010 Best Paper in Alzheimer’s Disease Neuroimaging: New Investigator Award from the Alzheimer’s Association.


Christin SANDER

Dr. Christin Sander is a research fellow at the A. A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital and Harvard Medical School in Boston, MA, USA. She received her Ph.D. in Electrical Engineering and Computer Science from Massachusetts Institute of Technology, and Master degrees from University and Imperial College London. Her research focuses on multi-modal imaging of the brain with combined PET and fMRI. 



Dr Philip Scheltens studied at the VU University, Amsterdam, The Netherlands, gaining his MD in 1984, and PhD (Magnetic Resonance Imaging in Alzheimer’s disease) in 1993. 
Dr Scheltens is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam, as well as Honorary Professor of Neurology at University College London. From 2011-2015 he has been the scientific director of the Dutch Pearlstring Institute (PSI). In 2012 he initiated the national dementia plan in the Netherlands, called the “Deltaplan Dementie” and was appointed as vice-chair of the board in 2013. He is founder of, and has directed since 2000 the VUmc Alzheimer Center, which under his directorship produced to date over 54 PhD theses. 
He has authored >715 peer reviewed papers and >50 book chapters and co-edited several textbooks. His work is widely cited as evidenced by a current Hirsch factor of 91. In 2015 his first Dutch book entitled “het Alzheimer Mysterie” was published (Arbeiderspers), which entered the bestseller list in 2 weeks. 
He was elected member of the Royal Academy of Arts and Sciences in 2011 and was elected as member of the Board of Directors in 2015.


A/Prof Villemagne graduated Cum Laude from the National University of Buenos Aires in 1983. He was awarded a Post-Doctoral Fellowship in Nuclear Medicine by the National Atomic Energy Commission in 1984, and continued his post-graduate studies at the Division of Nuclear Medicine at Johns Hopkins Medical Institutions.  He subsequently furthered his molecular neuroimaging training at the National Institute on Drug Abuse, NIH, and the University of Pittsburgh.  He now holds the appointment of Senior Research Fellow in Neuroscience at the PET Centre, Austin Hospital.  Since 2003, he has performed several preclinical studies of new tracers for Aβ and tau with in vitro techniques and animal models and human PET and SPECT studies - including blood metabolite analysis and kinetic modeling for quantification of binding parameters- at Austin Health. A/Prof Villemagne have been principal or co-investigator in several national and international grants. A/Prof Villemagne has authored or co-authored ten book chapters, several requested reviews on dementia imaging, and more than 200 original research publications, with senior or first author papers on PET research in leading international peer-reviewed journals, particularly in the field of neuroreceptor and amyloid imaging studies.  He has been invited to chair and present at national and international meetings in the area of biomarkers for Alzheimer’s disease and neurodegeneration.  Among other honours, he has received the Foerderer Fund for Excellence Award from The Children’s Hospital of Philadelphia in 2002, the JAAME Fellowship from Japan in 2007 and the ANSTO Nuclear Medicine Award in 2010.  More recently, he received the de Leon Prize in Neuroimaging - Senior Scientist by the Alzheimer’s Association International Society to Advance Alzheimer's Research and Treatment (2013), and the Christopher Clark Award for the Continuing Advancement in the Field of Human Amyloid Imaging, Miami (2014).


I am an Associate Professor and the Head of the Division of Clinical Geriatrics at Karolinska Institutet in Sweden. I have an engineering background from the Royal Institute of Technology (KTH) in Stockholm and I obtained my PhD in 2009. I did a postdoc at the Centre for Neuroimaging Sciences, Institute of Psychiatry, King’s College London. 
I have been working with neuroimaging within different neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) for almost fourteen years. The focus of my research group is on magnetic resonance imaging (MRI), both structural and functional techniques, but we also work with positron emission tomography (PET) and computed tomography (CT). Due to the complexity and heterogeneity of the different neurodegenerative disorder, using one biomarker is probably not enough. Investigating patterns of atrophy or disease are probably more useful. The need for advanced statistical tools (multivariate data analysis, machine learning and graph theory) is important when combing large amounts of data from multiple neuroimaging modalities.  Analyzing and combining different imaging techniques with advanced mathematical and statistical methods will hopefully aid in diagnosing the diseases in an early stage, monitor disease progression, and to understand the underlying mechanisms of different diseases.


               Share Share

News | general information | Archives | Press Presse | Newsletters | DOCUMENTS